The first big test of Pfizer’s Arena buyout clears a PhIII in bid to catch up to Zeposia

Pfizer couldn’t let Bristol Myers Squibb be the only Big Pharma with an S1P drug for UC after Zeposia earned an FDA nod last May. Now, Pfizer is inching closer to delivering on its $6.7 billion bid to rival BMS.